NOBROLA

A TWO-STAGE SIMON DESIGN PHASE II STUDY OF SINGLE AGENT OLAPARIB FOR NON-BRCA METASTATIC BREAST CANCER PATIENTS WITH HRD

CLINICAL TRIAL DETAILS

TO EVALUATE OLAPARIB IN ADVANCED TRIPLE NEGATIVE BREAST CANCER (TNBC) PATIENTS WITH HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) AND NO GERMLINE BRCA1/2 MUTATIONS (gBRCA1/2mut).

NOBROLA AT CLINICALTRIALS.GOV

COUNTRY

STATUS

TUMOR TYPE

PHASE

SITES

Triple-Negative Breast Cancer

114 (6 eligible/treated)

IIa

Spain

Completed

PRESS RELEASE

AACR 2018

SCIENTIFIC IMPACT

The Breast 2024 publication

BLOG ARTICLES RELATED

Spotlight – NOBROLA trial for advanced triple-negative breast cancer

TRIAL SITES

Hospital del Mar (Spain) Hospital Universitari Sant Joan de Reus (Spain) Instituto Valenciano de Oncología (IVO) (Spain) Hospital Universitario Ramón y Cajal (Spain) Complejo Hospitalario Universitario A Coruña (CHUAC) (Spain) Hospital Universitario Virgen de la Victoria (Spain) Hospital Universitario Virgen del Rocío (Spain) Hospital Clínico Universitario Lozano Blesa (Spain) Institut Català d' Oncologia L'Hospitalet (ICO) (Spain) Institut Català d' Oncologia Badalona (ICO) (Spain) Hospital Arnau de Vilanova de Valencia (Spain) Complejo Asistencial Universitario de Salamanca (Spain) Institut Català d' Oncologia Girona (ICO) (Spain) Hospital Universitario Doce de Octubre (Spain) Complejo Hospitalario de Jaén (Spain) Clinica Universitaria de Navarra (CUN) (Spain) MD Anderson Cancer Center Madrid (Spain)